Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding Ltd
(OP:
RHHBF
)
362.50
UNCHANGED
Streaming Delayed Price
Updated: 9:30 AM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roche Holding Ltd
< Previous
1
2
3
4
5
6
7
Next >
Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics
October 20, 2021
Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
October 20, 2021
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ...
Via
Benzinga
Exposures
Product Safety
Why Are Atea Pharmaceuticals Shares Plunging Today?
October 19, 2021
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate...
Via
Benzinga
Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting
October 18, 2021
The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with...
Via
Benzinga
Exposures
Product Safety
Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation
October 08, 2021
Roche Holdings AG's (OTC: RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer's disease. Gantenerumab is...
Via
Benzinga
Exposures
Product Safety
Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection
October 01, 2021
The FDA has granted Emergency Use Authorization (EUA) to Laboratory Corp of America Holdings's (NYSE: LH) combined home collection kit to detect COVID-19 and...
Via
Benzinga
Exposures
COVID-19
Product Safety
BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial
October 01, 2021
BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial...
Via
Benzinga
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
September 30, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (...
Via
Benzinga
Exposures
COVID-19
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
September 27, 2021
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19...
Via
Benzinga
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is...
Via
Benzinga
Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy Patients
September 24, 2021
Roche Holding AG (OTC: RHHBY) has highlighted new data for its oral spinal muscular atrophy (SMA) treatment Evrysdi, showing its benefits when given to pre-...
Via
Benzinga
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
September 24, 2021
The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited...
Via
Benzinga
Exposures
COVID-19
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know
September 15, 2021
Biogen Inc's (NASDAQ: BIIB) Spinraza (nusinersen), spinal muscular atrophy (SMA) drug launched in early 2017, faces new competition from Roche Holdings AG's...
Via
Benzinga
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
September 14, 2021
Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating...
Via
Benzinga
Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition
September 09, 2021
Roche Holdings AG (OTC: RHHBY) has agreed to acquire TIB Molbiol Group for an undisclosed amount. The deal is expected to close in Q4 of 2021. The...
Via
Benzinga
MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis
September 08, 2021
MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast...
Via
Benzinga
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
September 07, 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC:...
Via
Benzinga
Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy
September 07, 2021
Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington's Disease (HD). Spark...
Via
Benzinga
See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate
August 31, 2021
AC Immune SA (NASDAQ: ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC: RHHBY), have announced topline data from Phase...
Via
Benzinga
After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US
August 27, 2021
Following a consultation from the FDA, Roche Holdings AG (OTC: RHHBY) has decided to withdraw its immunotherapy, Tecentriq (atezolizumab), to treat a type of...
Via
Benzinga
Exposures
Product Safety
Shape Therapeutics, Roche Form $3B RNA Editing Collaboration
August 24, 2021
Shape Therapeutics Inc announced a multi-target strategic collaboration and license agreement with Roche Holding AG (OTC: RHHBY) for RNA editing technology....
Via
Benzinga
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
August 20, 2021
The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent...
Via
Benzinga
Exposures
COVID-19
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage
August 17, 2021
Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after...
Via
Benzinga
Exposures
COVID-19
Product Safety
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
August 09, 2021
AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3...
Via
Benzinga
Genentech's Polivy Plus R-CHP Shows Prolonged Survival In Newly Diagnosed DLBCL Patients
August 09, 2021
Genentech, a member of Roche Holdings AG (OTC: RHHBY), announced that the pivotal Phase 3 POLARIX trial met its primary endpoint in people with previously...
Via
Benzinga
Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg
August 04, 2021
SoftBank Group Corp (OTC: SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC: RHHBF), making it one of the largest investors of the Roche,...
Via
Benzinga
Roche's Tecentriq As Adjuvant Treatment Under Priority Review With FDA For Early Lung Cancer
August 03, 2021
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) Tecentriq (atezolizumab), as adjuvant treatment for...
Via
Benzinga
Exposures
Product Safety
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
August 02, 2021
Following the June update that
Via
Benzinga
Exposures
COVID-19
Product Safety
Roche's Faricimab US Application For Ocular Diseases Under Priority Review
July 29, 2021
The FDA has accepted Roche Holding AG's (OTC: RHHBY) Biologics License Application seeking approval for faricimab in neovascular of wet age-related macular...
Via
Benzinga
Exposures
Product Safety
Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings
July 27, 2021
Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.